Research
Compiled From the Literature.
Citable overviews of research peptides, certificate-of-analysis interpretation, HPLC purity standards, and laboratory practice — compiled from peer-reviewed literature for researchers evaluating compounds.
Topic
Sort
33 articles
- Verification GuideCOAs & Testing
Purity vs Fill Accuracy: Why One Number Is Not Enough
Two independent measurements, and why suppliers publish only the first
- VerificationCOAs & Testing
How to Verify a Peptide COA in Three Steps
A certificate is only worth what its verification path is worth, and most of the market has no verification path at all
- VerificationCOAs & Testing
How to Spot a Fake Peptide COA: Seven Red Flags
Most bad certificates are not forgeries. They are real documents used to say something they do not say.
- Verification GuideCOAs & Testing
How to Read a Certificate of Analysis
What each figure on a peptide COA proves — and what it does not
- VerificationCOAs & Testing
Janoshik Testing Explained: How Every Eppix Batch Is Verified
What the laboratory measures, what its certificates report, and how to check any of ours on its database in two minutes
- Laboratory PracticeLab Practice
Peptide Reconstitution: The Laboratory Guide
Solvent choice, the arithmetic, and the handling errors that destroy material before an experiment starts
- Laboratory PracticeLab Practice
Peptide Storage and Shelf Life: The Laboratory Guide
Four degradation routes, two physical states, and why the dry solid is so much more forgiving than the solution
- RegulatoryRegulation
Are Peptides Legal in the US? A Plain-Language Overview
One statute does most of the work, "research use only" is a legal description rather than a disclaimer, and the July 2026 advisory vote changed less than it appeared to
- Sourcing GuideCOAs & TestingRegulation
How to Choose a Peptide Supplier in the US: A Nine-Point Checklist
Nine things that are checkable before you spend anything, ordered by how much they tell you
- Compound ComparisonTissue Repair
BPC-157 vs TB-500: The Research Comparison
Two compounds routinely sold as a pair, with different origins, different mechanisms and very different evidence quality
- Compound ComparisonMetabolic & GLP-1
Retatrutide vs Tirzepatide: Triple Against Dual
One extra receptor, one approval, and a gap in trial depth that the receptor count does not close
- Compound ComparisonMetabolic & GLP-1
Semaglutide vs Tirzepatide: The Only Head-to-Head Trial in the Class
One receptor against two, and the rare case where the comparison was actually run rather than inferred
- Sourcing GuideTissue Repair
BPC-157 in the US: Purity, Batch Certificates and What to Check
The most-searched research peptide in the US, and the four things worth checking before a vial is ordered
- Sourcing GuideTissue Repair
TB-500 in the US: The Thymosin β4 Fragment, Tested by Batch
What is actually in a TB-500 vial, why the naming confusion matters commercially, and how to verify a lot
- Sourcing GuideMetabolic & GLP-1
Retatrutide in the US: The Triple Agonist, and What Is Actually Published
A phase 2 compound with real trial data, no approval anywhere, and a research supply market moving faster than the evidence
- Sourcing GuideMetabolic & GLP-1
Tirzepatide in the US: Research-Grade, and How It Differs From the Pharmacy Product
The dual agonist with the deepest trial record in its class, and the distinction that matters when you buy it as a research material
- Sourcing GuideMetabolic & GLP-1
Semaglutide in the US: Research-Grade, Verified by Batch
The most-studied GLP-1 analog, the difference between a research vial and a prescription product, and what a certificate has to prove
- Sourcing GuideTissue Repair
GHK-Cu in the US: The Copper Peptide, and Why the Copper Is the Hard Part
A tripeptide-copper complex with a fifty-year literature, and a quality question most certificates do not answer
- Sourcing GuideGrowth Hormone
CJC-1295 and Ipamorelin in the US: The Blend, and What Each Half Does
Two compounds with different mechanisms sold in one vial, and the certificate problem that creates
- Sourcing GuideMetabolic & GLP-1Longevity
MOTS-c in the US: The Mitochondrial-Derived Peptide
A 16-residue peptide encoded in mitochondrial DNA, a decade of metabolic literature, and a July 2026 regulatory vote
- Sourcing GuideLongevity
NAD+ in the US: The Coenzyme, Not a Peptide
What NAD+ actually is, why it does not get a purity certificate that looks like a peptide certificate, and what the literature supports
- Sourcing GuideTissue RepairImmune & Inflammation
KPV in the US: The α-MSH Fragment in Inflammation Research
A tripeptide with a real preclinical literature, a July 2026 regulatory moment, and a supply market that has not caught up
- Sourcing GuideGrowth Hormone
Ipamorelin in the US: The Selective Secretagogue
A pentapeptide whose defining property is what it does not do, and a certificate check that suits a small molecule
- Sourcing GuideGrowth Hormone
Tesamorelin in the US: The GHRH Analog With Approved-Drug Data
The only compound in the GH-axis catalog with completed phase 3 trials, and why that does not transfer to a research vial
- Sourcing GuideMetabolic & GLP-1
Cagrilintide in the US: The Long-Acting Amylin Analog
The compound that made amylin the incretin field's second act, with published phase 2 data and no approval
- Sourcing GuideCognitive
Selank in the US: The Tuftsin Analog From the Russian Literature
A heptapeptide with a real research program published almost entirely in one language, and what that means for reading the evidence
- Sourcing GuideLongevity
Epitalon in the US: The Telomerase Claim, Examined
A four-residue peptide carrying one of the strongest claims in the field, and the thinnest independent evidence base to support it
- Sourcing GuideGrowth Hormone
Sermorelin in the US: GHRH(1-29), and the Approval That Was Withdrawn
The shortest fully active GHRH fragment, once an approved diagnostic and paediatric agent, now a research material again
- Sourcing GuideImmune & Inflammation
Thymosin Alpha-1 in the US: The Immune Peptide With Real Approvals Elsewhere
Approved in dozens of countries, never approved in North America, and sold here as a research material
- Sourcing GuideMetabolic & GLP-1Longevity
5-Amino-1MQ in the US: The NNMT Inhibitor That Is Not a Peptide
A small molecule in a peptide catalog, with a specific enzyme target and a certificate that should look different
- Sourcing GuideMetabolic & GLP-1
Eloralintide in the US: The Selective Amylin Agonist
The newest compound on the metabolic shelf, with a short but genuinely peer-reviewed public record
- Compound OverviewMetabolic & GLP-1
Tirzepatide: A Research Literature Overview
Dual GIP / GLP-1 receptor agonist: published research summary
- Compound OverviewTissue Repair
BPC-157: A Research Literature Overview
Body Protection Compound: published preclinical research summary
Research Use Only
Articles on this site summarize published preclinical research literature for use by researchers evaluating compounds for in-vitro laboratory study within the United States. Nothing on this site is medical advice or describes human or veterinary use.